Comparing APLS and oranges: caution with the use of direct-acting oral anticoagulants (DOACs) instead of warfarin in the treatment of antiphospholipid syndrome (APLS)

Matthew Benger, Jasper Vink, Luke Blagdon Snell, Karen Breen

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

A 63-year-old woman with known antiphospholipid syndrome (APLS) presented with catastrophic APLS and multiorgan dysfunction after a change in her anticoagulation from warfarin to rivaroxaban. Evidence suggests direct-acting oral anticoagulants (DOACs) like rivaroxaban may be less effective than warfarin in secondary prevention of thrombotic events in high-risk APLS patients.

Original languageEnglish
JournalBMJ case reports
Volume12
Issue number4
DOIs
Publication statusPublished - 1 Apr 2019

Keywords

  • Administration, Oral
  • Anticoagulants/therapeutic use
  • Antiphospholipid Syndrome/complications
  • Factor Xa Inhibitors/administration & dosage
  • Female
  • Humans
  • Middle Aged
  • Rivaroxaban/administration & dosage
  • Secondary Prevention
  • Thrombosis/etiology
  • Warfarin/therapeutic use

Fingerprint

Dive into the research topics of 'Comparing APLS and oranges: caution with the use of direct-acting oral anticoagulants (DOACs) instead of warfarin in the treatment of antiphospholipid syndrome (APLS)'. Together they form a unique fingerprint.

Cite this